Researchers have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of ...
Researchers engineered a retargeted HSV-1 oncolytic virus that selectively infects glioblastoma cells, delivers five ...
The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) plus pertuzumab as first-line therapy for unresectable or ...
The FDA has approved RYBREVANT FASPRO, the first subcutaneous amivantamab, for EGFR-mutated non small cell lung cancer (NSCLC), enabling five-minute administration with fewer infusion reactions. I ...
ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is ...
Real-world data from nearly 400 patients with advanced, unresectable melanoma show that a flipped, lower-dose ipilimumab ...
An international study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on ...
FDA has approved AKEEGA (niraparib and abiraterone) as the first precision therapy for BRCA2+ metastatic castration-sensitive ...
The results from HER2CLIMB-05 study, presented at the 2025 SABCS annual meeting, demonstrated that tucatinib (TUKYSA) added ...
One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali ...
GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell lung cancer, supported by early ARTEMIS 001 data showing durable responses in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback